Global Pharmaceutical Packaging Market 2025 – 2034

Reports Description

As per the Pharmaceutical Packaging Market analysis conducted by the CMI Team, the global pharmaceutical packaging market is expected to record a CAGR of 10.12% from 2025 to 2034. In 2025, the market size is projected to reach a valuation of USD 142.23 Billion. By 2034, the valuation is anticipated to reach USD 338.7 Billion.

To learn more about this report - request a sample report PDF

Pharmaceutical Packaging Market Overview

The global pharma packaging industry is a key component of the healthcare and materials system, providing a range of custom-designed products from blister packs to bottles, ampoules, vials, syringes, cartridges, pouches, and tubes. The formats of packaging ensure product safety, enhance shelf life, and aid patient compliance in the form of oral, injectable, topical, and inhalation drug delivery systems.

The market is experiencing robust growth momentum due to mounting global healthcare spending, the growing geriatric population, the spread of chronic diseases, and the boom in biologic and specialty drug production. Further, there is a growing need for tamper-evident, child-resistant, and sustainable pharmaceutical packaging that is dictating product innovation across the world.

Industry leaders like Amcor plc, Gerresheimer AG, West Pharmaceutical Services Inc., AptarGroup Inc., and Schott AG are heavily investing in innovative materials, eco-friendly packaging formats, and intelligent packaging technologies. These players are expanding their worldwide manufacturing bases, embracing circular economy strategies, and forging strategic collaborations to enhance supply chain resilience.

The challenges on this front are raw material price volatility, extremely stringent regulatory initiatives, and rising environmental pressures. In response, companies are adopting recyclable and biodegradable packaging material, automation, and digital traceability systems for assurance of compliance and sustainability. Changes in government policies, particularly in the context of ESG mandates and plastic consumption, continue to influence the competitive dynamics of the industry.

Pharmaceutical Packaging Market Key Growth Drivers

The Pharmaceutical packaging market Trends have tremendous growth opportunities due to several reasons:

• Rising Global Healthcare Expenditure: The increasing healthcare expenditure across the globe is one of the key drivers for the pharmaceutical packaging industry. With aging and growing populations, demand for medicines and medical treatments is on the rise, and therefore, there is a requirement for durable packaging solutions to safeguard drug efficacy and safety. For example, India's health spending is expected to grow to 3% of its GDP by 2024 from 1.2% in 2018, which represents a dramatic increase in healthcare investment. This increased expenditure results in increased production and distribution of drugs, thus increasing the demand for specialized packaging that is compliant with regulations and maintains product integrity.

• Growth of Biopharmaceuticals: Global growth in biopharmaceuticals like monoclonal antibodies, vaccines, and gene therapies is revolutionizing packaging requirements in the pharmaceutical sector. Biologics are more sensitive in character to environmental factors like light, temperature, and oxygen compared to traditional drugs and therefore demand advanced-level packaging forms with better barrier quality and controlled environment. This has prompted pharma companies to invest in proprietary containers such as pre-filled syringes, glass vials, and polymer-based systems. As per EvaluatePharma, biologic sales worldwide are anticipated to surpass $445 billion by 2025 with a 9% compound annual growth rate (CAGR). As these high-value therapies dominate the pipeline, especially in oncology and autoimmune diseases, pharmaceutical firms must ensure product stability and sterility throughout the supply chain. Consequently, packaging becomes not just a container but an enabler of drug efficacy and patient safety, stimulating demand for high-performance, regulated, and innovative solutions across the value chain.

• Emphasis on Sustainable Packaging: The push towards sustainability is compelling pharma firms to shift packaging strategies. Increasing government pressure and green consciousness are compelling industry players to cut down on plastics, use recyclable material, and adopt eco-friendly manufacturing practices. GlaxoSmithKline (GSK), for example, has committed to making all consumer health packaging reusable or recyclable by 2025. The company has already started phasing out PVC blister packs with paper-based blister packs and streamlining secondary packaging layers. At Novartis too, there are similar initiatives with the launch of recyclable mono-material packaging for a series of product ranges. These changes not only save the environment but also enhance brand reputation among progressively environmentally aware consumers. Governments of Europe are also imposing Extended Producer Responsibility (EPR), where pharmaceutical companies are required to take responsibility for and fund disposing of or recycling packaging waste. These combined environmental, regulatory, and corporate social responsibility pressures are reshaping the industry, and sustainable packaging is a key investment opportunity and source of innovation.

• Expansion of E-commerce in Pharmaceuticals: Pharmaceutical e-commerce has revolutionized packaging needs, with an increased focus on durability, tamper resistance, and product traceability. As more consumers seek online pharmacies, the logistics of bringing medicines directly to consumers require packaging that maintains the integrity of drugs during shipping. For instance, Amazon Pharmacy has home delivery of prescription medicines with packaging that protects temperature-sensitive materials and does not contaminate or tamper with products. Similarly, Capsule, a virtual pharmacy which is found in major American cities, uses same-day delivery along with packaging which maintains the product sterility and provides instructions for users straight onto the box. This model requires packaging to withstand environmental variations during transport, offer theft-proof features, and comply with labeling regulations. As telehealth and digital prescriptions become more mainstream, packaging design must evolve to accommodate faster logistics, personalization, and digital integration—such as QR codes linking to usage videos—making it a pivotal component of the growing e-pharmacy landscape.

Pharmaceutical Packaging Market Key Threats

The Pharmaceutical packaging market has several primary threats that will influence its profitability and future development. Some of the threats are:

• High Packaging Costs: Pharmaceutical packaging constitutes a collection of processes which will be tied up with gigantic material and production costs due to the advanced requirements of drug safety, traceability, and drug regulation. Blister packs, tamper-evident seals, and child-resistant containers involve high-precision engineering, viable packaging material, and strict quality control. For instance, biologics tend to require glass vials with silicone or fluoropolymer coating to avoid contact with the drug, which drives the cost considerably. Besides, packaging of controlled substances such as opioids needs to have multi-layer protection, anti-counterfeiting features, and batch tracking functionality. An example can be the implementation of serialized barcodes on every unit of medicine, which requires investment in high-end printing systems and software. Small and medium-sized pharmaceutical businesses tend to find it difficult to absorb these costs while keeping prices competitive. Moreover, utilization of sustainable materials while being eco-friendly also involves higher initial costs. These accumulated cost drivers restrict scalability, especially in price-sensitive markets, as an important hindrance to the large-scale adoption of advanced packaging technologies.

• Stringent Regulatory Compliance: The pharmaceutical packaging sector is regulated by stringent regulatory rules, and indeed this can be a significant deterrent, especially to new players and multi-geography companies. Packaging type and packaging material need to be compliant with country-specific regulations, e.g., the U.S. FDA compliance via tamper-evident packaging or EU compliance via child-proofing packaging and serialization codes. India's Drug Authentication and Verification Application (DAVA), for instance, requires exporters to affix a 2D barcode and serialization onto packaging to track medicines. Such compliance is expensive in terms of technology spent in labeling machinery, integrating databases, and validation procedures. Re-approval of even small packaging changes becomes necessary, causing product launch delays and more compliance costs. Such regulation demands, so precious to the safety of the patient, act as bottlenecks to operations and restrict freedom, especially in firms that have to introduce novel drugs or configurations of packaging simultaneously across various regions.

Pharmaceutical Packaging Market Opportunities

• Smart Packaging Solutions: Smart packaging is proving to be a significant opportunity to improve security, traceability, and compliance with regulations of patients in the pharma industry. Through the addition of sensors, RFID tags, and QR codes, packages are able to update the present state of the product, authenticate the product, and even remind patients to take medicine. A good example is the "CleverCap" pill bottle that monitors pill taking and reminds patients and caregivers in the case of a missed dose. This is also useful in chronic diseases like diabetes or hypertension, where it is crucial to adhere to the regimen stringently. Drug makers are also infusing tamper-evidence markings that turn colors when packaging has been compromised so that product integrity is maintained when shipped. In addition, refrigerated drugs like insulin can also be packaged with integrated temperature gauges to indicate to users in case storage procedures were compromised. These interactive functions enhance transparency, decrease medication errors, and offer valuable information for healthcare professionals, thereby making smart packaging an exciting horizon in patient-centered pharmacy care.

• Biodegradable Materials: Biodegradable packaging offers an enormous opportunity in minimizing the environmental impact of drug products. Polylactic acid (PLA), starch plastic, and cellulose film are making their way as alternatives to conventional petroleum-based polymers for drug packaging. For example, some European hospitals have tested the use of compostable pill pouches for dispensing over-the-counter medications to minimize plastic waste. On the same note, pharma firm Bormioli Pharma has launched glass and bio-based polymer pack lines that answer both regulatory and environmental needs. The biodegradable formats that degrade easily without microplastics will find takers among environmentally aware consumers as well as corporate sustainability missions. With challenges still in getting these materials to pharmaceutical safety and shelf life, innovation is bridging that chasm. With tighter environmental regulations and changing consumer needs, biodegradable packaging technologies are poised to become the primary drivers in shifting pharmaceutical logistics and product stewardship.

Pharmaceutical Packaging Market Category Wise Insights

By Formulation Type

• Oral Solids (Tablets & Capsules): Oral solids, including capsules and tablets, account for the largest percentage in pharmaceutical packaging owing to their wide consumption across the world, longer shelf life, and simplicity in administration. Oral solid packaging encompasses blister packs, strip packs, bottles, and unit-dose containers, which provide protection from moisture, contamination, and mechanical damage. Blister packaging is very commonly used because it delivers unit-dose precision and resistance to tampering. For example, ibuprofen and paracetamol are usually packaged in aluminum-PVC blister packs. Additionally, calendar-based labeling or smart packs is being increasingly utilized to improve patient compliance. With the accelerating prevalence of chronic conditions, e.g., diabetes and hypertension, demand for orally solid packaged medicines is increasing quickly, particularly in developing markets where access to cheaper generic medicines is widening. Regulatory requirements for serialization and anti-counterfeiting solutions also fuel innovation in oral solid packaging form.

• Injectables: Injectables, is the form of intravenous (IV), intramuscular, and subcutaneous formulations need very sterile and safe packaging so that the effectiveness of the drug is preserved and the patients are also kept safe. Glass vials, ampoules, pre-filled syringes, and cartridges are the most popular types of packages used for injectables. The packaging systems need to adhere to rigorous regulatory requirements regarding sterility, material compatibility, and tampering evidence. As examples, insulin and biologics such as monoclonal antibodies are routinely supplied in pre-filled syringes with safety-engineered caps. The surge in biologics and vaccines, including mRNA COVID-19 vaccines, has greatly increased the demand for sophisticated injectable packaging that will handle cold-chain logistics and dose precision. Auto-injectors and dual-chamber syringes are also gaining popularity due to ease of use and lower handling errors. Hospital-based treatments and self-injecting therapies, particularly in oncology and immunotherapy, are driving this sub-segment further.

• Liquids: Liquid pharmaceuticals, including syrups, suspensions, and solutions need special packaging to avoid contamination, leakage, and degradation by light or oxygen. Typical packaging includes PET or HDPE bottles, glass bottles, pouches, and dosage cups or droppers for accurate dosing. Child-resistant closures and tamper-evident closures are required for most OTC liquid drugs such as cough syrups or pediatric fever reducers. Amber glass is commonly employed to safeguard light-sensitive preparations like some antibiotics or multivitamin tonics. The packaging also needs to be compatible with active ingredients, particularly in multi-dose bottles that are utilized over a long period of time. With increasing demand for pediatric and geriatric products, easy-to-use and safe packaging is a priority. In addition, liquid nutraceuticals and herbal medications are becoming more popular, and that is pushing innovation in light, environmentally friendly packaging formats for direct-to-consumer markets and e-commerce solutions.

• Others: This segment includes specialty and less commonly found drug forms such as topical creams, ointments, transdermal patches, inhalers, suppositories, and nasal sprays. All of them require highly customized packaging based on their delivery type, duration, and method. For instance, metered-dose inhalers (MDIs) of asthma and COPD drugs need aluminum canisters with sensitively valve systems, whereas ointments are primarily filled in laminated tubes or collapsible aluminum tubes to prevent oxidation. Transdermal patches need to be packaged in foil-based or polymeric packaging to preserve drug integrity and controlled release. Packaging of these products needs to provide proper dosing, prevent the risk of contamination, and provide convenience to end users. Pump dispensers, single-dose sachets, and tamper-resistant applicators are newer developments in this field. Increased activity in dermatology, respiratory, and hormone therapy uses is increasing the scope of this diversified sub-segment in pharmaceutical packaging.

By Material

• Plastic & Polymers: Plastics and polymers dominate pharmaceutical packaging due to their affordability, lightness, flexibility, and ability to mold into complex shapes. Some of the most used ones include polyethylene (PE), polypropylene (PP), polyvinyl chloride (PVC), and polyethylene terephthalate (PET). They are widely applied in blister packs, bottles, jars, caps, and flexible pouches. HDPE bottles, for instance, are the norm for solid oral dosage forms, whereas PVC is applied in blister packs. Plastic packaging is also an excellent moisture barrier and is compatible with a broad range of formulations. Sustainability concerns are, however, compelling a trend towards recyclable or biobased polymers. Multilayer plastic laminates are also used for enhanced protection in liquid unit-dose packaging. With the growing need for child resistance and tamper evidence, advanced plastic molding and sealing technologies are increasingly being employed. Regulatory needs and transportation facilitation further increase their application in prescription as well as over-the-counter medicines globally.

• Glass: Glass is a critical material to be employed in the pharma packaging of pharmaceuticals, particularly injectable forms and photo-sensitive medications. Glass has superior chemical resistance, impermeability, and inertness and consequently finds extensive use in vials, ampoules, and pre-filled syringes. Borosilicate glass finds usage owing to its resistance against thermal shock and interaction with the drug content. For example, anticancer medication and vaccines are mostly filled in sterile glass containers to maintain drug stability. Glass also supports high-speed filling lines, which are critical for bulk production during public health crises like the COVID-19 pandemic. Nevertheless, risk of breakage, increased cost of transport, and regulatory challenges on delamination have prompted innovation such as silicon-coated and aluminosilicate glass to enhance resistance. Glass remains essential to certain critical care and high-potency medications, where ideal barrier protection and long-term stability cannot be undermined.

• Paper & Paperboard: Paper and paperboard packaging becomes more popular as secondary packaging of pharmaceuticals as it is printable, recyclable, and sustainably usable. Paper and paperboard packaging in the shape of cartons, boxes, leaflets, and labels is applied. Paper and paperboard packaging protects the primary package from damage at handling and transportation while serving as a substrate for labeling, branding, and usage instructions that are required by regulations. For example, tablets packed in blister packs are typically contained within paperboard cartons with patient information leaflets. Biodegradable and recyclable paperboard is now considered a favorable option for packaging over-the-counter medications such as painkillers and vitamins. Furthermore, business houses are experimenting with tamper-evident paper-based alternatives that limit plastic usage in external packaging. Pharmaceutical manufacturers are also using paperboard digital printing to include QR code for e-leaflets and dosage instructions. Regulatory guidelines and consumer pressure towards green packaging are forcing producers to shift towards FSC-certified and biodegradable paperboard options, especially in regulated and retail-focused pharmaceutical markets.

• Metal: Metal is used primarily in pharmaceutical packaging for high barrier application and product protection. The most common used metal is aluminum, which exists in blister pack foils, tubes, and canisters. For instance, effervescent tablets are packaged in aluminum tubes to protect them from moisture exposure and maintain reactivity. Aluminum foil in blister packaging provides outstanding protection against light, oxygen, and moisture essential for drug shelf life extension. In inhalation treatments, aluminum canisters play a crucial role in providing metered doses using devices like MDIs. Metal tubes are also utilized for creams and ointments that need non-reactive, collapsible packaging. Metal packaging also facilitates tamper-proof sealing and provides thermal stability for products that are exposed to fluctuating temperatures during storage or transportation. While metal is more costly and dense than plastic, its strength, chemical resistance, and recyclability render it crucial in certain high-value pharmaceutical packagings.

Pharmaceutical Packaging Market Impact of Latest Tariff Policies

Recent tariff policies have significantly impacted the global pharmaceutical packaging market, mainly by raising the costs of raw materials such as aluminum, glass, plastics, and specialty polymers. When countries like the U.S., China, and EU nations impose higher tariffs on imported products to protect domestic industries, pharmaceutical packaging companies have to bear higher operational expenses and lower margins. These rising tariffs are disturbing long-standing international supply chains, leading businesses to reconsider their sourcing practices and doubt the viability of global procurement for essential packaging parts.

In response, many players in the pharmaceutical packaging industry are shifting towards regional manufacturing hubs and exploring localized supply chains to mitigate tariff-related risks. While this transition supports long-term supply chain resilience and cost optimization, it may slow down innovation and availability in developing economies that rely heavily on imports. Additionally, such policies could hinder access to advanced sustainable materials, affecting the industry's overall move towards eco-friendly and compliant packaging solutions worldwide.

Report Scope

Pharmaceutical Packaging Market Regional Perspective

The Pharmaceutical packaging market can be divided across different regions such as North America, Europe, Asia-Pacific, and LAMEA. This is a cursory overview of each region:

• North America: North America is the leading market for pharmaceutical packaging due to a developed pharmaceutical sector, high-standard healthcare facilities, and stringent regulatory standards. The United States, featuring huge pharmaceutical players such as Pfizer, Johnson & Johnson, and Merck, accounts for regional-leading demand for quality-compliant packaging solutions. The area has a high take-up of green materials and smart packaging systems, like serialization and anti-counterfeiting technology as mandated by the U.S. Drug Supply Chain Security Act (DSCSA). Greater use of prescription drugs, particularly for the elderly, enhances the future demand for blister packs, bottles, and prefilled syringes. Canada is a significant contributor as well, particularly due to its emphasis on generic drug manufacturing. Other rising trends in self-medication and home healthcare solutions are also fueling the demand for easy-to-use, tamper-evident formats of packaging. The area's propensity for innovation and high healthcare expenditure even more solidifies its leadership in pharmaceutical packaging across the world.

• Europe: Europe holds a significant portion of the world's pharmaceutical packaging market with its strong pharmaceutical production base, strict regulatory environment, and growing demand for sustainable solutions. Key contributors are Germany, France, and Switzerland, which are home to global leaders in packaging and pharmaceutical companies. The region focuses on eco-friendly and recyclable materials for meeting EU sustainability objectives, thus driving packaging innovation in primary and secondary formats. European Medicines Agency (EMA) regulations push the use of child-resistant, tamper-evident, and easily labeled packaging to ensure regulatory compliance and patient safety. Growing incidence of chronic diseases and an aging population are also generating demand for tailored, easy-to-use packaging, especially for injectables and oral solids. Further, R&D investments and the introduction of biologics and specialty drugs are generating demand for sterile and high-barrier packaging. Europe's pharma export market further propels packaging demand for international shipment and regulatory compliance.

• Asia-Pacific: Asia-Pacific is the fastest-growing pharma packaging region, driven by increasing pharma production, increased healthcare access, and growing ageing population. The region of China and India has become the production centers of both generic and branded drugs worldwide and thus has triggered robust demand for affordable and large-volume packaging material. Initiatives by local authorities facilitating local pharmaceutical industries and foreign investment are fueling local growth. Further, rising urbanization, improved health awareness, and rising middle classes are increasing domestic drug consumption. Blister packs, plastic bottles, and sachets are convenient pack types due to low costs and adherence to safety standards. Flexible and sustainable packaging innovations are catching up, particularly in Japan and South Korea. Harmonization of regulations and investment in modernization of manufacturing units for export is further consolidating the region's global standing. With low-cost competitive labor and plentiful raw materials, Asia-Pacific is a key contributor to world pharmaceutical packaging dynamics.

• LAMEA: The LAMEA market provides strong growth opportunities for the pharma packaging segment due to the forces of urbanization, reforms in healthcare, and increased pharma imports and exports. Latin America, led by Brazil and Mexico, is witnessing increasing consumption of drugs due to increasing healthcare coverage and escalating incidences of non-communicable diseases. The Middle East, represented by nations such as Saudi Arabia and the UAE, is investing in local manufacturing of pharmaceuticals and regulations modernization, hence increasing demand for high-quality packaging materials such as glass vials and blister packs. Africa, although in development, demonstrates increasing acceptance of essential medicines, hence increasing demand for cost-effective and long-lasting packaging, mainly for oral solids and liquid products. Across LAMEA, efforts at serialized and tamper-evident packaging to eliminate counterfeit drugs are increasingly important. While infrastructural and regulatory issues persist, economic diversification across the region and global alliances are gradually improving packaging standards and creating growth prospects in the longer term.

Pharmaceutical Packaging Market Key Developments

In recent years, the pharmaceutical packaging market has experienced several crucial changes as the players in the market strive to grow their geographical footprint and improve their product line and profits by using synergies.

• In November 2023, Amcor Plc, a global leader in environmentally responsible packaging solutions, announced a Memorandum of Understanding (MoU) with NOVA Chemicals Corporation, a prominent supplier of sustainable polyethylene. Under this agreement, Amcor will source mechanically recycled polyethylene (rPE) from NOVA Chemicals for use in flexible packaging films. This collaboration supports Amcor’s broader commitment to advancing packaging circularity by incorporating higher volumes of recycled content into its product offerings.

• In July 2023, Constantia Flexibles launched REGULA CIRC, a next-generation pharmaceutical packaging solution made with coldform foil. The innovation replaces conventional PVC with a PE sealing layer, significantly reducing plastic usage while increasing the aluminum proportion. This material shift enhances the sustainability of the packaging and facilitates more efficient recycling and material recovery processes.

• In April 2023, Südpack unveiled PharmaGuard Blister, a polypropylene-based blister packaging solution. Designed specifically for the pharmaceutical sector, this packaging provides an excellent water vapor barrier along with robust UV and oxygen resistance, ensuring improved product protection while aligning with eco-friendly packaging standards.

These important changes facilitated the companies to widen their portfolios, to bolster their competitiveness, and to exploit the possibilities for growth available in the pharmaceutical packaging market. This phenomenon is likely to persist since most companies are struggling to outperform their rivals in the market.

Pharmaceutical Packaging Market Competitive Landscape

The Pharmaceutical packaging market is highly competitive, with a large number of product providers globally. Some of the key players in the market include:

• Amcor plc
• Becton Dickinson and Company
• AptarGroup Inc.
• Drug Plastics Group
• Gerresheimer AG
• Schott AG
• Owens Illinois Inc.
• West Pharmaceutical Services Inc.
• Berry Global Inc.
• WestRock Company
• SGD Pharma
• International Paper
• Comar LLC
• CCL Industries Inc.
• Vetter Pharma International
• Others

These firms apply a sequence of strategies to enter the market, including innovations, mergers and acquisitions, as well as collaboration.

These companies deploy several market-entry and expansion strategies such as mergers & acquisitions, technological innovation, regional expansion, and collaborations with pharmaceutical manufacturers. Strategic focus areas include the development of eco-friendly materials, smart packaging (e.g., RFID & serialization), child-resistant and senior-friendly packaging designs, and customized primary packaging for injectables and biologics.

The global pharmaceutical packaging market is evolving with players increasingly focusing on sustainability, regulatory compliance, and automation to maintain competitive advantage. For instance, Amcor plc is leading in the development of recyclable flexible packaging and high-barrier film technology, aligning with pharmaceutical sustainability goals.

Gerresheimer AG is expanding its high-value glass and polymer vial production, responding to increased biologics and vaccine demand. Schott AG has launched a low-delamination glass vial series that reduces particle contamination—vital for injectable drug safety. West Pharmaceutical Services continues to invest in smart packaging technologies such as Daikyo Crystal Zenith systems for biologics.

Moreover, Berry Global is scaling up production of child-resistant closures and PET bottles tailored for OTC and prescription drugs. CCL Industries, through its Healthcare & Specialty division, is innovating in tamper-evident labeling solutions that comply with EU Falsified Medicines Directive (FMD). Companies are also integrating digital supply chain solutions to improve traceability and regulatory adherence.

Regional players are gaining ground by emphasizing cost-efficiency, localized production, and regulatory adaptability. For example, SGD Pharma is increasing its footprint in Asia through joint ventures, while Comar LLC is investing in cleanroom expansions in North America to meet rising demand for primary plastic packaging components. The competitive ecosystem is increasingly shaped by ESG investments, GMP-certified facilities, and the ability to serve the rising demand from biopharmaceutical and generic drug segments, especially in emerging markets.

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America